Antibody Therapies for Chronic Pain
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (30 June 2021) | Viewed by 644
Special Issue Editors
Interests: neurobiology; brain and spinal cord physiology; ion channels; electrophysiology; neuropharmacology; pain medicine; chronic pain; novel therapeutics
Interests: pain physiology; chronic pain; neuropharmacology; behavioral pharmacology; anesthesiology; pain medicine; novel therapeutics
Special Issue Information
Dear Colleauges,
Chronic pain affects 1 in 5 people globally. Opioids for the management of chronic pain are limited by serious side effects and abuse potential. In 2017 opioids were the leading cause of death in Americans under the age of 50 (Katz, 2017). Therefore, more effective non-opioid-based therapeutics with higher efficacy and fewer side effects are urgently needed for chronic pain treatment.
One potential avenue for new therapeutics for chronic pain are antibody-based therapies. Among antibody-based therapies and immune modulators, at least six antibodies are currently in Phase III trials that are targeted to reduce immune factors, including CGRP for migraine, semaphorin 4D (Huntington’s disease), nerve growth factor, tau, α-synuclein, and amyloid β (Alzheimer’s disease, ALS, Parkinson’s disease), demonstrating current thinking and the diversity of available targets for immunotherapy in neurological disorders (Kaplon and Reichert, 2019; Alpaugh and Cicchetti, 2019).
In this Special Issue we will focus on the potential of antibody therapies for the treatment and management of chronic pain.
Dr. Sascha R. A. Alles
Prof. Dr. Karin Westlund-High
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody therapies
- chronic pain
- non-opioid therapeutics
- ion channels
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
